Immunophenotype-defined sub-populations are common at diagnosis in childhood B-cell precursor acute lymphoblastic leukemia

Leukemia

Volumn 25, Issue 10, 2011, Pages 1652-1657

  Obro N F ^a   Marquart, H V ^a   Madsen, H O ^a   Ryder, L P ^a   Andersen, M K ^a   Lausen, B ^a   Albertsen, B K ^b   Wehner, P S ^c   Helgestad, J ^b   Schmiegelow, K ^a,d  

^a Rigshospitalet   (Denmark)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

^c ODENSE UNIVERSITY HOSPITAL   (Denmark)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CD19 ANTIGEN; CD20 ANTIGEN; CD22 ANTIGEN; CD34 ANTIGEN; CD45 ANTIGEN; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; HLA DR ANTIGEN;

ACUTE LYMPHOBLASTIC LEUKEMIA; CANCER PATIENT; CHILD; CHILDHOOD LEUKEMIA; CLINICAL ARTICLE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE REARRANGEMENT; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; LETTER; LYMPHOCYTE SUBPOPULATION; PRE B LYMPHOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ACUTE DISEASE; ANTIGENS, CD; CHILD; HUMANS; IMMUNOPHENOTYPING; LEUKEMIA, B-CELL; POLYMERASE CHAIN REACTION;

EID: 80054028198     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2011.136     Document Type: Letter

References (9)

1. Marusyk A, Polyak K. Tumor heterogeneity: causes and consequences. Biochim Biophys Acta 2010; 1805: 105-107.
2. Al-Mawali A, Gillis D, Lewis I. The role of multiparameter flow cytometry for detection of minimal residual disease (MRD) in acute myeloid leukemia (AML). Am J Clin Pathol 2009; 131: 16-26.
3. Borowitz MJ, Pullen DJ, Winick N, Martin PL, Bowman WP, Camitta B. Comparison of diagnostic and relapse flow cytometry phenotypes in childhood acute lymphoblastic leukemia: implications for residual disease detection: a report from the children's oncology group. Cytometry B Clin Cytom 2005; 68: 18-24. (Pubitemid 41566359)
4. Choi S, Hendersen MJ, Ewans E, Beesley AH, Sutton R, Bahar AY et al. Relapse in children with acute lymphoblastic leukemia involving selection of a pre-existing drug-resistant subclone. Blood 2007; 110: 632-639. (Pubitemid 47105402)
5. Obro NF, Madsen HO, Ryder LP, Andersen MK, Schmiegelow K, Marquart HV. Approaches for cytogenetic and molecular analyses of small flow-sorted cell populations from childhood leukemia bone marrow samples. J Immunol Methods 2011; e-pub ahead of print 6 May 2011.
6. Stahnke K, Eckhoff S, Mohr A, Meyer LH, Debatin KM. Apoptosis induction in peripheral leukemia cells by remission induction treatment in vivo: selective depletion and apoptosis in a CD34+ subpopulation of leukemia cells. Leukemia 2003; 17: 2130-2139. (Pubitemid 37428378)
7. Lucio P, Parreira A, van den Beemd MW, van Lochem EG, van Wering ER, Baars E et al. Flow cytometric analysis of normal B cell differentiation: a fram of reference for the detection of minimal residual disease in precursor B-ALL. Leukemia 1999; 13: 419-427. (Pubitemid 29108081)
8. Dick JE. Stem cell concepts renew cancer research. Blood 2008; 112: 4793-4807.
9. Dworzak MN, Gaipa G, Schumich A, Maglia O, Ratei R, Veltroni M et al. Modulation of antigen expression in B-cell precursor acute lymphoblastic leukemia during induction therapy is partly transient: evidence for a drug-induced regulatory phenomenon. Results of the AIEOP-BFM-ALL-FLOW-MRD-Study Group. Cytometry B Clin Cytom 2010; 78: 147-153.